Authors' reply

Schneider, A.; Enck, P.; Streitberger, K.
May 2006
Gut;May2006, Vol. 55 Issue 5, p744
Academic Journal
A response by A. Schneider, P. Enck, K. Streitberger to a letter to the editor about their article "Acupuncture Treatment in Irritable Bowel Syndrome" in the May 2006 issue is presented.


Related Articles

  • Stratification by sex and subgroup is necessary for RCT on lBS. Bian, Z. X. // Gut;May2006, Vol. 55 Issue 5, p743 

    A letter to the editor is presented in response to the article "Acupuncture Treatment in Irritable Bowel Syndrome," by A. Schneider, P. Enck, K. Streitberger, C. Weiland, S. Bagheri, S. Witte, H-C. Friederich, W. Herzog and S. Zipfel in the May 2006 issue.

  • Which End Point Is More Comprehensive in Reflecting Changes in Irritable Bowel Syndrome Treatment Trials? Gholamrezaei, Ali; Nemati, Kianoosh; Emami, Mohammad Hassan // American Journal of Gastroenterology;Nov2009, Vol. 104 Issue 11, p2859 

    A letter to the editor is presented in response to the article "Adequate relief in a treatment trial with IBS patients: a prospective assessment," by M. C. F. Passos, A. J. Lembo, and L. A. Conboy in the November 2009 issue.

  • Ideas on Trial Design in Acupuncture for IBS. Ma Tingting // American Journal of Gastroenterology;Mar2010, Vol. 105 Issue 3, p699 

    A letter to the editor is presented in response to a study by Lembo and colleagues regarding that analyzes the efficacy of acupuncture for irritable bowel syndrome treatment (IBS).

  • A Prospective Randomized Trial of Mosapride vs. Placebo in Constipation-Predominant Irritable Bowel Syndrome. Mansour, Nabil M; Ghaith, Ola; El-Halabi, Mustapha; Sharara, Ala I // American Journal of Gastroenterology;May2012, Vol. 107 Issue 5, p792 

    A letter to the editor is presented regarding the prospective double-blind placebo controlled trial that compares placebo and mosapride in the treatment of constipation-predominant irritable bowel syndrome (C-IBS) patients.

  • Diagnosis and treatment of irritable bowel syndrome. Dalton, Christine B.; Drossman, Douglas A. // American Family Physician;2/15/1997, Vol. 55 Issue 3, p875 

    States that irritable bowel syndrome is a common disorder characterized by symptoms of abdominal pain with diarrhea and/or constipation. How to diagnose this disorder using the symptom-based Rome criteria; What discovery has aided the management of patients with this disorder; Treatment for...

  • Alosetron to return to market. Young, Donna // American Journal of Health-System Pharmacy;7/15/2002, Vol. 59 Issue 14, p1323 

    Reports on the U.S. Food & Drug Administration's approval of a supplemental drug that permits restricted marketing of alosetron hydrochloride by GlaxoSmithKline PLC. Reasons of the company for previously withdrawing the drug; Drug dosage and administration; Effectiveness in treating irritable...

  • Pharmacologic Treatment of the Irritable Bowel Syndrome: A Systematic Review of Randomized, Controlled Trials. Jailwala, Jeegar; Imperiale, Thomas F.; Kroenke, Kurt // Annals of Internal Medicine;7/18/2000, Vol. 133 Issue 2, p136 

    Evaluates the efficacy of pharmacologic agents for the irritable bowel syndrome. Effectiveness of smooth-muscle relaxants when abdominal pain is the predominant symptom; Lack of statistically significant evidence for the use of psychotropic agents; Effectiveness of loperamide for diarrhea;...

  • Hypnotherapy and Efficacy--Irritable Bowel Syndrome. McEwen, Kate // Positive Health;May2012, Issue 194, p1 

    The article discusses the use of hypnosis to treat Irritable Bowel Syndrome (IBS). It describes the prevalence of IBS in Great Britain, along with the symptoms of IBS such as abdominal contractions, bloating and nausea. Information on hypnosis is given, including the process of hypnosis therapy....

  • Rifaximin for IBS without constipation.  // Internal Medicine Alert;2/15/2011 Supplement 2, p23 

    The article reports that the use of rifaximin for patients with irritable bowel syndrome (IBS) without constipation has provided a statistically significant improvement in global symptoms, bloating, abdominal pain and stool consistency.


Read the Article


Sign out of this library

Other Topics